3 versions

CosmeticWhat changed in ENGROSSED IN SENATEcompared with REPORTED TO SENATE (Jan 28, 2026)

Technical corrections only. The two versions of the bill, S. 1157, are substantively identical, with changes limited to the legislative status information (e.g., "Reported with an amendment" vs. "Passed the Senate June 8, 2026"). There are no substantive policy changes between v2 and v3.

S. 1157119th CongressIntroduced Mar 26, 2025

Women and Lung Cancer Research and Preventive Services Act of 2025

Passed SenateHealthSubstantive

View bill text

Sponsor: Sen. Smith, Tina [D-MN]
Committees: Health, Education, Labor, and Pensions Committee (primary)
Last action: Jun 9, 2026

Bottom line

This bill mandates an interagency review to enhance federal efforts in lung cancer research and prevention, with a specific focus on improving outcomes for women and underserved populations.

What it actually does

This bill directs the Secretary of Health and Human Services, in consultation with the Secretaries of Defense and Veterans Affairs, to conduct a comprehensive review of federal programs and strategic plans related to lung cancer research, prevention, diagnosis, and treatment. The review specifically aims to identify and address knowledge gaps concerning lung cancer in women and populations with few known risk factors, and to improve screening rates among recommended populations. A report summarizing findings and recommending changes is due to Congress within two years.

Proponents argue

Supporters argue this bill is crucial for addressing critical disparities in lung cancer research and care, particularly for women and individuals without traditional risk factors, who are often overlooked. They contend that a coordinated federal review will lead to a better understanding of the disease's etiology in these groups, earlier diagnosis, and more effective treatment strategies, ultimately improving public health outcomes.

Opponents contend

Critics might argue that while the intent is laudable, such a broad review could potentially duplicate existing efforts within federal agencies or that the mandate is too general without specific funding allocations. Some may also contend that existing mechanisms are sufficient for identifying research gaps and that this bill might create unnecessary bureaucratic overhead without guaranteeing substantial new insights or direct patient benefits.

The bill is concise and clearly written, making it accessible for a quick and thorough understanding of its objectives and provisions.

Section 2(a)

Mandate for Interagency Lung Cancer Review

prominently featuredstraightforward

This provision directs the Secretary of Health and Human Services, in collaboration with the Secretaries of Defense and Veterans Affairs, to conduct a thorough review of all federal programs and strategic plans related to lung cancer. The primary goals are to identify and close knowledge gaps concerning lung cancer in women and populations with few known risk factors, and to enhance lung cancer screening rates among recommended groups.

GroupImpactMechanismScale

GroupWomen and populations with few known lung cancer risk factorsImpactPotential for improved understanding of lung cancer etiology, better screening, diagnosis, and treatment strategies.MechanismFederal agencies will conduct a review and update programs based on findings.ScaleNational, impacting research and public health strategies.

GroupFederal agencies (HHS, DoD, VA)ImpactIncreased coordination and focused effort on specific lung cancer research areas.MechanismMandated interagency consultation and review.ScaleOperational impact on federal health agencies.

Supporters argue

Supporters contend that this focused review is essential to address the unique aspects of lung cancer in women and those without traditional risk factors, leading to more equitable and effective public health interventions. It ensures federal efforts are aligned and responsive to emerging research needs.

Critics contend

Some critics might argue that while the intent is good, a broad review without specific directives or new funding might not yield significant new insights beyond what ongoing research already provides, potentially leading to bureaucratic overhead without substantial change.

Tradeoffs

The tension lies between the desire for comprehensive review and the potential for bureaucratic inertia or resource diversion if not managed effectively. It aims to balance broad inquiry with targeted outcomes.

Section 2(b)

Specific Areas of Review and Research Opportunities

prominently featuredstraightforward

This section details what the interagency review must cover. It includes assessing current research findings and federally funded projects, identifying knowledge gaps, and exploring new research opportunities. These opportunities include evaluating environmental and genomic factors in women's lung cancer, improving screening rates, and advancing technology like biomarker testing for better risk assessment, diagnosis, and treatment. It also requires reviewing public health strategies for screening and diagnosis.

Section 2(c)

Congressional Report on Review Findings

prominently featuredstraightforward

Within two years of the bill's enactment, the Secretary of Health and Human Services must submit a report to specific Congressional committees. This report must summarize the research findings, ongoing projects, and knowledge gaps identified during the review. It also needs to describe any changes made to federal programs based on the review's findings and recommend any further changes, noting statutory or other barriers to their implementation.

About this analysis. AI-Generated from the official bill text and available committee reports. Gaps in available data are noted explicitly. Verify important details with the official Congress.gov record.

CosmeticWhat changed in ENGROSSED IN SENATEcompared with REPORTED TO SENATE (Jan 28, 2026)

S. 1157119th CongressIntroduced Mar 26, 2025

Women and Lung Cancer Research and Preventive Services Act of 2025

Passed SenateHealthSubstantive

View bill text

Sponsor: Sen. Smith, Tina [D-MN]
Committees: Health, Education, Labor, and Pensions Committee (primary)
Last action: Jun 9, 2026

Bottom line

This bill mandates an interagency review to enhance federal efforts in lung cancer research and prevention, with a specific focus on improving outcomes for women and underserved populations.

What it actually does

Proponents argue

Opponents contend

The bill is concise and clearly written, making it accessible for a quick and thorough understanding of its objectives and provisions.

Section 2(a)

Mandate for Interagency Lung Cancer Review

prominently featuredstraightforward

GroupImpactMechanismScale

Supporters argue

Critics contend

Tradeoffs

Section 2(b)

Specific Areas of Review and Research Opportunities

prominently featuredstraightforward

Section 2(c)

Congressional Report on Review Findings

prominently featuredstraightforward